Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

From WikiMD's Wellnesspedia

(Redirected from 11 beta hydroxylase deficiency)

Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency
Classification and external resources
OMIM202010
eMedicinearticle/117012
Human steroidogenesis. The action of 11β-hydroxylase is seen in red box at right.
11β-OH CAH is autosomal recessive.

Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency is a rare, autosomal recessive disorder that is part of the larger family of congenital adrenal hyperplasia (CAH) disorders. It is caused by a deficiency in the enzyme 11β-hydroxylase, which is crucial for the synthesis of corticosteroids in the adrenal glands. This deficiency leads to an accumulation of precursor steroids, which are then diverted to androgen synthesis, resulting in symptoms of androgen excess.

Etiology and Pathophysiology[edit | edit source]

The disorder is caused by mutations in the CYP11B1 gene, which encodes the enzyme 11β-hydroxylase. This enzyme is responsible for the conversion of 11-deoxycortisol to cortisol and deoxycorticosterone (DOC) to corticosterone in the adrenal cortex. A deficiency in 11β-hydroxylase leads to decreased production of cortisol and corticosterone, with a consequent increase in ACTH secretion by the pituitary gland. The increased ACTH levels stimulate the adrenal gland, leading to an overproduction of androgenic steroids.

Clinical Features[edit | edit source]

Patients with 11β-hydroxylase deficiency typically present with signs of androgen excess, such as virilization in females, precocious puberty in males, and accelerated growth and bone maturation in both sexes, which may lead to short stature as growth plates close early. Hypertension is a distinguishing feature of this form of CAH, due to the accumulation of deoxycorticosterone, a potent mineralocorticoid.

Diagnosis[edit | edit source]

Diagnosis is based on clinical presentation, biochemical testing showing elevated levels of 11-deoxycortisol and androgens, and genetic testing confirming mutations in the CYP11B1 gene. The differential diagnosis includes other forms of CAH, particularly 21-hydroxylase deficiency, which is more common.

Treatment[edit | edit source]

Treatment focuses on replacing deficient corticosteroids, usually with glucocorticoids such as hydrocortisone, to suppress ACTH production and reduce androgen synthesis. Mineralocorticoid replacement is not typically required, as hypertension is usually due to the mineralocorticoid effect of DOC. Blood pressure management is also crucial. In cases of severe virilization, additional treatments may be necessary.

Prognosis[edit | edit source]

With early diagnosis and appropriate treatment, individuals with 11β-hydroxylase deficiency can lead normal lives, although they require lifelong monitoring and medication. The main complications arise from improper management of glucocorticoid therapy and the consequences of excess androgen exposure.

See also[edit | edit source]


Pediatric glossary of terms | Glossary of medical terms | Dictionary of pediatrics


Resources[edit source]

Latest articles - Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

PubMed
Clinical trials
UpToDate

AI tools[edit source]

Generative AI tools and links to learn more on Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency: ChatGPT - Bing Chat - Google Gemini. (caution advised).


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.


Contributors: Prab R. Tumpati, MD